Amy K. Patick

Treatment of HCV Infection by Targeting MicroRNA

Harry L.A. Janssen, Hendrik W. Reesink, Eric Lawitz et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Viracept (Nelfinavir Mesylate, AG1343):  A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease

Stephen W. Kaldor, Vincent J. Kalish, Jay F. Davies et al. · Journal of Medicinal Chemistry · 1997 · 617 citations · Full text

Immunology, Antiviral Drug, Nelfinavir Mesylate +17

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

Victor DeGruttola, Lynn P. Dix, Richard T. D’Aquila et al. · Antiviral Therapy · 2000 · 330 citations · Full text

Pharmacotherapy, Antiviral Drug, Drug Resistance +19

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes

David A. Matthews, Peter S. Dragovich, S. E. Webber et al. · Proceedings of the National Academy of Sciences · 1999 · 316 citations

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

Wade Blair, Chris Pickford, S.L. Irving et al. · PLoS Pathogens · 2010 · 296 citations · Full text

Immunology, Molecular Biology, Antiviral Drug +19